CAFC Again Says Teva Induced Infringement on Carvedilol, Assures Holding...
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday underscored its October 2020 ruling that generic company, Teva Pharmaceuticals, was liable for induced infringement of...
View ArticleGSK Argues Unusual Facts of Case Behind Teva’s SCOTUS Petition Limits CAFC’s...
On August 19, British brand name pharmaceutical firm GlaxoSmithKline (GSK) filed a brief with the U.S. Supreme Court opposing a petition for writ of certiorari filed by generic drugmaker Teva...
View ArticleUSPTO Agrees to Withdraw Claims & Continuations Rules
PRESS RELEASE: GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO’s motion to dismiss its litigation...
View ArticleTafas Objects to Vacatur in Claims and Continuations Appeal
Late this evening attorneys representing Dr. Triantafyllos Tafas filed a Reply to Motion for Dismissal of Appeal and Request for Remand. In this filing Tafas points out that the decision made by USPTO...
View ArticleJUST IN: Federal Circuit Denies Vacatur in USPTO Rules Case
Earlier today the Chief Judge Paul Michel of the United States Court of Appeals for the Federal Circuit issued an Order declaring the pending appeal of Dr. Tafas and GlaxoSmithKline moot due to the...
View ArticleTafas and GlaxoSmithKline Awarded Jefferson Medal by NJIPLA
Tafas and GSK were recognized with this prestigious award for their successful legal challenge to the claims and continuations rules made final in 2007 by the United States Patent and Trademark...
View ArticleLicensing Executives Society Announces 2010 Deals of Distinction™ Awards
In May 2009, Genzyme Corporation acquired the worldwide rights to a potential breakthrough treatment for Multiple Sclerosis (MS) along with three marketed oncology products from Bayer Healthcare...
View ArticlePatent Business: Deals, Acquisitions & Licenses July 2012
This deal will give GSK exclusive rights to BENLYSTA, which is a human monoclonal antibody that inhibits B-cell activating factor (BAFF) approved for treatment of systemic lupus erythematosus. It is...
View ArticleTafas v. Dudas/Doll – 5 Years Later But Still Very Pertinent
Although such Final Rules were widely criticized by most companies in the United States, a sole individual, Dr. Triantafyllos Tafas, a co-inventor of a computerized automated microscope, stood alone...
View ArticlePharma Law and Business – A Monthly Roundup for January 2013
Not surprisingly, 2013 began with a predictable rush of interesting news. So here are some of the most recent highlights, from court rulings and medical study findings to FDA doings and steps taken to...
View ArticlePharma Scandals: Bribery, Insider Trading and Paula Deen
The summer may be in full swing, but the torrent pace of news and interesting developments has not subsided at all. Hot days simply yield hot stories. Unarguably, the most sensational item over the...
View ArticleWhy NIH/Industry Partnerships Matter: Ask an HIV patient
Those who believe that patents aren't important or that companies would undertake the rigors of commercial development with only non-exclusive licenses don't understand the realities facing innovators...
View ArticleFederal Circuit Says Teva Induced Infringement of GSK Patent on Congestive...
In GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., the United States Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s motion for judgment as a matter of law...
View ArticleU.S. Government Sides with Teva in Skinny Label SCOTUS Fight
The U.S. Solicitor General on Wednesday filed an amicus brief with the United States Supreme Court advising it to grant Teva Pharmaceuticals’ petition for writ of certiorari relating to generic...
View ArticleSCOTUS Kills Hope for Eligibility Certainty and Nixes Teva’s ‘Skinny Label’...
On May 15, the U.S. Supreme Court issued an order list denying petitions for writ of certiorari filed to appeal several patent rulings, including a pair of 35 U.S.C. § 101 subject matter eligibility...
View Article
